Research library · Genomics
Secondary findings are a choice about a different testing question
Draft • Research checked 4 October 2026 • AI-assisted DomDNA editorial content. No independent clinical review or publication is claimed. General education, not individual medical advice.
You can agree to testing for one medical question and still need a conversation about other findings. Broad genomic analyses can look beyond the original reason for the test. Some services offer a defined search for medically relevant findings unrelated to that reason.
The useful question is not simply whether you want “all your DNA information”. It is what additional analysis is offered, what results could be returned and how that choice will be recorded.
Primary and secondary are purpose labels
The NHGRI secondary-finding glossary describes a potentially medically useful finding unrelated to the original reason for examining the genome. “Secondary” does not mean unimportant or unreliable; it describes the relationship to the test's primary question.
The MedlinePlus explanation discusses possible benefits, uncertainty, stress and follow-up. Its page includes historical gene-list versions, so a number copied from an older paragraph should not be presented as the current policy of every service.
The NHGRI Secondary Genomics Findings Service describes a particular research-service pathway including confirmation and counselling. That is an example of a structured return process, not a promise that another laboratory or consumer platform uses the same pathway.
Keep the service's own policy beside the general explanation. The existence of guidance does not mean all tests search for the same findings or return them on the same terms.
A hypothetical consent conversation
Imagine that a test is ordered to investigate a neurological concern. The service also offers a separate search for a defined set of medically actionable findings. This is an editorial scenario, not a recommendation about any individual's test.
The first question is what the additional search includes. The second is what kind of result qualifies for return. The third is what happens if a result is found: confirmation, communication, further assessment and support.
The person may want time to consider the choice. They may prefer to involve someone they trust, while keeping control of their own information. A meaningful choice should not be reduced to clicking a box whose consequences remain unexplained.
It is also reasonable to ask what declining the additional analysis means for the primary test. Do not assume that every service separates the choices in the same way.
Define “all results” before asking for them
Broad sequencing can produce far more data than a clinical service interprets and returns. An additional-findings policy is not a commitment to report every unusual sequence or every uncertain association.
A result outside the primary question still needs appropriate evidence and a return pathway. More findings are not automatically more useful information. Uncertain or poorly contextualised information can generate confusion without answering a practical question.
This article does not reproduce a current gene list or recommend an opt-in decision. Lists and policies can change, and the relevant scope belongs to the specific service and date.
When reviewing consent information, ask for the named policy version rather than relying on a general internet list. Record any unresolved question before deciding.
Follow-up is part of the information
An additional finding may have implications for medical assessment and, sometimes, relatives. Before testing, ask who will explain a result and how any confirmation is handled. Ask what happens if the primary question remains unanswered but an unrelated finding is returned.
These are practical communication questions, not a prediction that a finding will occur. Avoid generic numerical odds unless they come from a population and pathway that actually fit the proposed testing.
A consumer upload report and a clinical return-of-results service may have very different processes. A colourful badge should not be mistaken for a counselling and confirmation pathway.
What you can do with this
Your next step is to obtain the additional-findings information for the actual test. Write down the scope, available choices and contact route for questions. If you want time to consider it, ask before the specimen is analysed.
After a decision, keep a copy of the wording you agreed to and the date. This makes later questions about what was searched easier to answer.
The purpose is to make an informed choice about a distinct analysis, not to treat extra genetic information as automatically desirable or automatically alarming.
For general lifestyle learning, DomDNA’s educational quiz does not offer genomic testing or return secondary findings.
Original source and access ledger
- NHGRI secondary genomic finding
sourceDate: 2026-10-02
type: Official glossary
population: Broad genomic analysis
endpoint: Finding unrelated to primary purpose
supportedClaimAndLimit: Secondary describes test-purpose relationship; no personal finding probability used.
fundingAndConflicts: Official resource or project documentation; not a personal-benefit trial or endorsement. Institutional authorship does not establish clinical review of this draft.
accessEvidence: Official source page, documentation or primary abstract text accessed via web search/open on 2026-10-04. Indexed text was used where direct opening was incomplete; no complete study-methods or supplement appraisal claimed.
researchDate: 2026-10-04
correctionStatus: Access-date source check only; no comprehensive correction, retraction, policy-version or guideline surveillance claimed.
sourceWordLimit: 200
quoteWords: 0
sourceUseBudget: 200-word aggregate source-derived limit across article and adaptations; no verbatim quotations. Short central claims retained; hypothetical examples and administrative suggestions are original editorial material, not study findings.
- MedlinePlus secondary findings
sourceDate: Accessed 2026-10-04; includes historical 2021 list and 2025 bibliography
type: Official genetics education
population: Clinical exome and genome testing
endpoint: Additional findings and choice
supportedClaimAndLimit: Explains potential information, stress and choices; historical list counts are not represented as every service's current policy.
fundingAndConflicts: Official resource or project documentation; not a personal-benefit trial or endorsement. Institutional authorship does not establish clinical review of this draft.
accessEvidence: Official source page, documentation or primary abstract text accessed via web search/open on 2026-10-04. Indexed text was used where direct opening was incomplete; no complete study-methods or supplement appraisal claimed.
researchDate: 2026-10-04
correctionStatus: Access-date source check only; no comprehensive correction, retraction, policy-version or guideline surveillance claimed.
sourceWordLimit: 200
quoteWords: 0
sourceUseBudget: 200-word aggregate source-derived limit across article and adaptations; no verbatim quotations. Short central claims retained; hypothetical examples and administrative suggestions are original editorial material, not study findings.
- NHGRI Secondary Genomics Findings Service
sourceDate: Accessed 2026-10-04; date not extracted
type: Official research-service description
population: Eligible NHGRI research pathways
endpoint: Confirmation, counselling and return process
supportedClaimAndLimit: Describes one structured service, not the pathway of every laboratory or consumer upload provider.
fundingAndConflicts: Official resource or project documentation; not a personal-benefit trial or endorsement. Institutional authorship does not establish clinical review of this draft.
accessEvidence: Official source page, documentation or primary abstract text accessed via web search/open on 2026-10-04. Indexed text was used where direct opening was incomplete; no complete study-methods or supplement appraisal claimed.
researchDate: 2026-10-04
correctionStatus: Access-date source check only; no comprehensive correction, retraction, policy-version or guideline surveillance claimed.
sourceWordLimit: 200
quoteWords: 0
sourceUseBudget: 200-word aggregate source-derived limit across article and adaptations; no verbatim quotations. Short central claims retained; hypothetical examples and administrative suggestions are original editorial material, not study findings.
Download exact original article Markdown · Download exact source and unsent social pack
Finished companion media
Silent films, slides and source captions on the separate dashboard. Original preview and historical product limits remain in their captions. No social campaign has been sent.